Xarelto Lawsuit Update: New Allegations Made in Xarelto Lawsuits

September 23, 2015 – – BloodThinnerHelp.com reports today on the allegations that are being made against the manufacturers of Xarelto. A majority of the lawsuits filed against the manufacturers, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson, make similar allegations concerning the blood thinner, mostly that usage of the drug led to uncontrollable internal bleeding events due to the nature of how the drug operates and that these incidents led to serious injury or death. For more information on the Xarelto lawsuits, click here.

Allegations Made in the Xarelto Lawsuits:

All of the federally filed lawsuits against the manufacturers of Xarelto are currently consolidated in a multidistrict litigation in the Eastern District of Louisiana. The MDL is presided over by U.S. District Judge Eldon Fallon. In addition to the federal MDL, there is also a Mass Tort Group in Philadelphia where more Xarelto lawsuits are consolidated.

The lawsuits in both of these legal systems were consolidated in the first place because they all make similar allegations. The lawsuits filed make the following allegations as the basis for their lawsuits:

1. The manufacturers of Xarelto failed to adequately warn patients and doctors about the real risks of Xarelto and the risk of irreversible uncontrollable bleeding that may occur.

2. There is a design defect with Xarelto because there is no safe anticoagulation solution, or antidote. This posed greater risks to patients because there is no reversal agent in the event of internal bleeding.

3. The manufacturers of Xarelto deliberately concealed knowledge of these irreversible internal bleeding risks and failed to inform doctors how to stabilize patients.

4. The manufacturers of Xarelto were negligent by releasing Xarelto onto the market with the knowledge that there was no antidote.

5. The manufacturers of Xarelto were negligent by misrepresenting Xarelto as a safe blood thinner in the product’s marketing materials.

6. Xarelto does not provide greater benefits than products that already exist on the market and work in a safer manner, such as Warfarin.

The Controversy Surrounding Xarelto:

Xarelto was first released onto the United States market in 2011 after receiving FDA approval. The drug was initially released to treat deep vein thrombosis, atrial fibrillation, and to be used in patients who have recently undergone hip or knee replacement surgeries. Since then, several studies have linked Xarelto to dangerous adverse events including brain hemorrhages, pulmonary embolism, gastrointestinal bleeds, stroke, and uncontrollable internal bleeding.

“We are determined to pursue justice for anyone who has been harmed by Xarelto usage.” Xarelto attorney Marc Goldich said, “If you or a loved on have been harmed by Xarelto contact us immediately. We expect to see even more cases filed now that the MDL has been formed.”

For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Marc Goldich
866-425-8902
1500 Walnut Street, 4th Floor, Philadelphia, PA 19102.

ReleaseID: 60004345